Real‐world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis

Real‐world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis

Guselkumab is an IL-23 inhibitor approved for moderate-to-severe plaque psoriasis that has demonstrated safety and efficacy in phase III clinical trials . However, there is scarce data regarding its drug survival in clinical practice.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of dermatology (1951) 2021-09, Vol.185 (3), p.660-662
Hauptverfasser: Iznardo, H., Vilarrasa, E., López‐Ferrer, A., Puig, L.
Format: Artikel
Sprache:eng
Schlagworte:
Monoclonal antibodies
Psoriasis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Guselkumab is an IL-23 inhibitor approved for moderate-to-severe plaque psoriasis that has demonstrated safety and efficacy in phase III clinical trials . However, there is scarce data regarding its drug survival in clinical practice.
ISSN:0007-0963
1365-2133
DOI:10.1111/bjd.20416